Widely used:Recently Viewed
Clear All
$165 Mln
--
0.53
--
0
-36.37 %
--
--
--
-1388568
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Caribou Biosciences (CRBU)
| -67.36 | -5.56 | 16.88 | -59.61 | -56.24 | -- | -- |
|
BSE Sensex
| 13.08 | -1.05 | 2.13 | 24.69 | 11.60 | 16.47 | 11.89 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
|
|---|---|---|
|
Caribou Biosciences (CRBU)
| -8.76 | -58.38 |
|
S&P Small-Cap 600
| 13.89 | -17.42 |
|
BSE Sensex
| 18.74 | 4.44 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$165.36 Mln
$33.11 Mln
$0.00 Mln
$261.65 Mln
$27.33 Mln
High
$1.50 - 8.33
90,362,800
NASDAQ: CRBU
Berkeley, CA
https://cariboubio.com
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product... candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California. Address: 2929 7th Street, Berkeley, CA, United States, 94710 Read more
The total asset value of Caribou Biosciences Inc (CRBU) stood at $ 404 Mln as on 30-Jun-24
The share price of Caribou Biosciences Inc (CRBU) is $1.87 (NASDAQ) as of 04-Oct-2024 16:00 EDT. Caribou Biosciences Inc (CRBU) has given a return of -56.24% in the last 3 years.
Caribou Biosciences Inc (CRBU) has a market capitalisation of $ 165 Mln as on 02-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Caribou Biosciences Inc (CRBU) is 0.53 times as on 02-Oct-2024, a 83% discount to its peers’ median range of 3.12 times.
Since, TTM earnings of Caribou Biosciences Inc (CRBU) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Caribou Biosciences Inc (CRBU) and enter the required number of quantities and click on buy to purchase the shares of Caribou Biosciences Inc (CRBU).
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California. Address: 2929 7th Street, Berkeley, CA, United States, 94710
The CEO & director of Dr. Rachel E. Haurwitz Ph.D.. is Caribou Biosciences Inc (CRBU), and CFO & Sr. VP is Dr. Rachel E. Haurwitz Ph.D..
There is no promoter pledging in Caribou Biosciences Inc (CRBU).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Caribou Biosciences Inc. (CRBU) | Ratios |
|---|---|
|
Return on equity(%)
|
-36.37
|
|
Operating margin(%)
|
-436.06
|
|
Net Margin(%)
|
-372.78
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Caribou Biosciences Inc (CRBU) was $0 Mln.
$0.08
